Research has indicated that the anti-tumor effects of metformin are mainly due to the activation of AMP-activated protein kinase (AMPK) and inhibition of mammalian targets of rapamycin (mTOR) (Dowling et al., 2007). This evidence concerns the gene MTOR and neoplasm.